By continuing to use our service, you agree to our use of cookies. Further. (“Theratechnologies” or “the Company”) (TSX: TH) (NASDAQ: THTX), a biopharmaceutical company focused on the development and commercialization of innovative therapies, today announced the strengthening of its global commercial. US Headquarters. Theratechnologies' (TH) Senior Vice President and Chief Medical Officer Dr. Theratechnologies (TSX: TH) (NASDAQ: THTX) is a biopharmaceutical company focused on the development and commercialization of innovative therapies addressing unmet medical needs. July 24 - Heron Therapeutics: Heron is turning to layoffs for the second time in 13 months to cut. : 001-35203 Mr. Montréal, Québec, Canada . 2015 Peel Street, 11th Floor Montréal, Québec Canada H3A 1T8 Phone: 514 336-7800 Fax: 514 331-9691. Theratechnologies was founded in 1993 and currently employs more than 150 people in Canada, the United States and Europe. Cookies are used to offer you a better browsing experience and to analyze our traffic. (“Theratechnologies” or the “Company”) (TSX: TH) (NASDAQ: THTX), a biopharmaceutical company focused on the development and. Theratechnologies Draws Down on US$20 Million Second Tranche Under its Term Loan Facility With Affiliates of Marathon Asset Management. Theratechnologies (TSX: TH) (NASDAQ: THTX) is a biopharmaceutical company focused on the development and commercialization of innovative therapies addressing unmet medical needs. By continuing to use our service, you agree to our use of cookies. (“Theratechnologies” or the “Company”) (TSX: TH) (NASDAQ: THTX), a biopharmaceutical company focused on the development and commercialization of innovative therapies,. We also use them to share usage. The reported ($0. Cookies are used to offer you a better browsing experience and to analyze our traffic. MONTREAL, July 23, 2021 /CNW Telbec/ - Theratechnologies Inc. (NASDAQ:THTX) Q2 2022 Earnings Conference Call July 14, 2021 8:30 AM ET. [email protected] Reports Financial Results for the Third Quarter of Fiscal 2022 and Provides Business Update T. THERATECHNOLOGIES INC. 10% most volatile stocks in CA Market. Theratechnologies (TSX: TH) (NASDAQ: THTX) is a biopharmaceutical company focused on the development and commercialization of innovative therapies addressing unmet medical needs. The business had revenue of $27. VANCOUVER, British Columbia, Nov. 13, 2022 (GLOBE NEWSWIRE) -- Theratechnologies Inc. Cookies are used to offer you a better browsing experience and to analyze our. . Theratechnologies Stock (NASDAQ: THTX) stock price, news, charts, stock research, profile. Theratechnologies is currently developing a platform of proprietary peptides called SORT1+ Technology TM for cancer drug development targeting SORT1 receptors. (TSX-V: TLT, Forum) has demonstrated proof-of-concept for its Canadian-made COVID-19 vaccine. The abstract and poster can be found on Theratechnologies’ website. (“Theratechnologies”, the “Company”, or “we”) (TSX: TH) (NASDAQ: THTX), a biopharmaceutical company focused on the development and commercialization of innovative therapies, today announced that it has completed the previously announced consolidation of the issued. a biopharmaceutical company focused on the development and commercialization of innovative therapies, today initiated enrollment of patients in the basket portion of the first-in-human study of TH1902, Theratechnologies’ investigational lead peptide drug conjugate (PDC) for the treatment of sortilin-expressing. The SORT1 receptor plays a significant role in protein internalization, sorting and trafficking. Our research pipeline focuses on specialized therapies addressing unmet medical needs in HIV, nonalcoholic. T. C. 2015 Peel St 11TH Fl, Montreal, Quebec, H3A 1T8, Canada. 40%. - Cash, bonds and money market funds of US$22. 40 f102M H1. 1. /NOT FOR DISTRIBUTION TO UNITED STATES OF AMERICA WIRE SERVICES OR DISSEMINATION IN THE UNITED STATES OF AMERICA/. It engages in addressing medical needs of patients with Human Immunodeficiency Virus (HIV). (TSX: TH) announced today that the Supreme Court of Canada has granted its appeal and dismissed 121851 Canada Inc. Theratechnologies (TSX: TH) (NASDAQ: THTX) is a biopharmaceutical company focused on the development and commercialization of innovative therapies addressing unmet medical needs. Stockhouse. is a pharmaceutical company. Get the latest Sernova Corp (SVA) real. Cookies are used to offer you a better browsing experience and to analyze our traffic. Following the release, Knight will hold a conference call and audio webcast. S. When this page refreshes you will be logged in with the new address. MONTREAL, June 29, 2023 (GLOBE NEWSWIRE) -- Theratechnologies Inc. 4. Stockhouse. By continuing to use our service, you agree to our use of cookies. Biopharmaceutical company Theratechnologies (TH) has closed its bought deal public offering after raising over C$58 million in proceeds. 72%. Theratechnologies last announced its earnings data on September 26th, 2023. TH | July 20, 2023. (THTX) Stock Price, Quote, latest community messages, chart, news and other stock related information. (2021-12-06 | TSX:TH) Theratechnologies Submits Supplemental Biologics License Application to FDA Advancing Development of IV Push Trogarzo® for Patients Living With HIV. The FDA granted fast track designation to TH1902 as a single agent for. 26, 2022 (GLOBE NEWSWIRE) -- Theratechnologies Inc. (2022-07-27 | TSX:TH) Theratechnologies Announces Closing of Funding of $40 Million Under the Terms of its Credit Agreement Stockhouse. About Theratechnologies. (“Theratechnologies” or the “Company”) (TSX: TH) (NASDAQ: THTX), a. 8 and 1. m. Theratechnologies (TH) and partners contributed $2 million for a research project for a new treatment for metastatic cancer. 81 million for the quarter. 16%. Company Participants. Theratechnologies (TSX: TH) (NASDAQ: THTX) is a biopharmaceutical company focused on the development and commercialization of innovative therapies addressing unmet medical needs. We currently market. com uses cookies on this site. (Theratechnologies) (TSX: TH) (NASDAQ: THTX), a biopharmaceutical company focused on. Senior Director, Investor Relations. Theratechnologies (TSX: TH) (NASDAQ: THTX) is a biopharmaceutical company focused on the development and commercialization of innovative therapies addressing unmet medical needs. (2021-11-23 | TSX:TH) Theratechnologies Announces Renewal of Shelf Prospectus and Registration Statement; At-The-Market Facility to be Extended. By continuing to use our service, you agree to our use of cookies. Register for your free account today at data. MONTREAL, Feb. (TSX: TH, Forum) noted that its Q1 2022 consolidated sales grew 20%, supported by 35% growth in sales of EGRIFTA SV formulation. 08). By continuing to use our service, you agree to our use of cookies. com. Theratechnologies Reports Financial Results and Business Updates for the Fourth Quarter and Full Year Fiscal 2022. Cenicriviroc (CVC) is a novel, orally administered, chemokine receptor type 2 and 5 antagonist that showed antifibrotic potential in preclinical and phase IIb studies of nonalcoholic steatohepatitis (NASH). com. See the latest Theratechnologies Inc stock price (THTX:XNAS), related news, valuation, dividends and more to help you make your investing decisions. 12, 2023 (GLOBE NEWSWIRE) -- Theratechnologies Inc. Unveiling Silvercorp's golden potential at the Ying Mining District. ) Clinical-stage pharmaceutical company Theralase Technologies Inc. Visit the TSX ETF Investor Centre to access our screener and comparison tool. D. Trogarzo is a CD4-directed post-attachment HIV-1 inhibitor. Theratechnologies Announces Certain Preliminary Q3 2023 Financial Highlights. (2021-06-30 | TSX:TH) CORRECTION: Theratechnologies to Announce Financial Results for Its Second Quarter Fiscal 2021. Follow. Cookies are used to offer you a better browsing experience and to analyze our traffic. Theratechnologies (TSX: TH) (NASDAQ: THTX) is a biopharmaceutical company focused on the development and commercialization of innovative therapies addressing unmet medical needs. Theratechnologies inc. 22, 2023 (GLOBE NEWSWIRE) -- B2Gold Corp. Theratechnologies Reports Financial Results for the Third Quarter of Fiscal 2022 and Provides Business Update. com uses cookies on this site. Paul Levesque - President. Cookies are used to offer you a better browsing experience and to analyze our traffic. TH1902 is a first-in-class PDC targeting SORT1, that consists of 2 molecules of docetaxel attached to the TH19P01 peptide via a cleavable succinyl linker. TH | September 5, 2023. T. Stockhouse. Montreal-based biopharmaceutical company Theratechnologies Inc. MONTREAL, Sept. THTX | Complete Theratechnologies Inc. Stockhouse. Amendments Allow Theratechnologies to Maintain Minimum Liquidity of US$15 Million up to and until October 31, 2023. The company had revenue of $20. 17% from a day low at $1. According to 3 analysts, the average rating for THTX stock is "Buy. T. (TSE:TH) posted its quarterly earnings data on Tuesday, September, 26th. [at noodls] - Montreal, Canada - April 17, 2015 - Theratechnologies Inc. Theratechnologies . TO) stock quote, history, news and other vital information to help you with your stock trading and investing. Stockhouse. . We also use them to share usage. Theratechnologies Inc. Headquarters. Theratechnologies (TSX: TH) (NASDAQ: THTX) is a biopharmaceutical company focused on the development and commercialization of innovative therapies addressing unmet medical needs. com uses cookies on this site. It is the Company’s proprietary. 26 +15. Cookies are used to offer you a better browsing experience and to analyze our traffic. (2015-05-15 | TSX:TH) Authorization to Discontinue Class Action Proceedings Against Theratechnologies Granted. In the United States, Trogarzo ® (ibalizumab. Stockhouse. Theratechnologies layoffs. - Cash, bonds and money market funds of US$22. m. Theratechnologies (TSX: TH) (NASDAQ: THTX) is a biopharmaceutical company focused on the development and commercialization of innovative therapies addressing unmet medical needs. MONTREAL, Jan. lgibson. 03, 2021 (GLOBE NEWSWIRE) -- Theratechnologies Inc. Theratechnologies affirms fiscal 2022 revenue to be in the range of $79 million and $84 million for full fiscal 2022, or growth of the commercial portfolio to be in the range of 13% and 20% as compared to the 2021 fiscal year. Theratechnologies (TSX: TH) (NASDAQ: THTX) is a biopharmaceutical company focused on the development and commercialization of innovative therapies addressing unmet medical needs. (2022-10-26 | TSX:TH) Theratechnologies Reports Data Showing High Expression of Sortilin (SORT1) in Multiple Solid Tumors from Tissue Microarrays. THTX | Complete Theratechnologies Inc. 31, 2023 (GLOBE NEWSWIRE) -- Theratechnologies Inc. 5% workforce reduction. 4%. Q3 2023 consolidated revenue of $20. 20% from a day low at $1. Share your ideas and get valuable. View recently published Stock News reports from independent reports and journalists. - Q3 2022 North American Revenue Growth of 19%. Presented in part at the XVI International AIDS Conference; August 13–18, 2006; Toronto, Canada (abstracts TUP30058 AND THLB0218). La Bourse de Toronto a perdu. High expression of the sortilin (SORT1) receptor correlates with decreased survival in triple‐negative breast cancer (TNBC) patients. Stockhouse. [email protected] Inc: Overview. Theratechnologies Announces 1-for-4 Reverse Stock Split. Microsoft to invest $500M in Quebec AI economy. We also use them to. Statut du système de négociation. By continuing to use our service, you agree to our use of cookies. Senior Director, Investor Relations. TH1902, the leading product candidate derived from the SORT1+ Technology, is a first-in-class peptide-drug. View Company Info for Free. T. Theratechnologies (TH) has taken home a 2021 ADRIQ Innovation Award in the Life Sciences category. Investor Relations. Message Board Total Posts: 4. Biopharmaceutical company Theratechnologies Inc. This news release constitutes a “designated news release” for the purposes of the. Theratechnologies (TSX: TH) (NASDAQ: THTX) is a biopharmaceutical company focused on the development and commercialization of innovative therapies addressing unmet medical needs. We also use them to share usage information with our partners. 81 million for the quarter. 00 to $36. By continuing to use our service, you agree to our use of cookies. 65 per cent to C$1. In collaboration with the University of Manitoba (UM), the company demonstrated that its photodynamic compound (PDC),. (“Theratechnologies” or the “Company”) (TSX: TH) (NASDAQ: THTX), a biopharmaceutical company focused on the development and commercialization of innovative therapies, today reported business highlights and financial results for the second quarter and first half of. Denis Boucher. MONTREAL, May 09, 2023 (GLOBE NEWSWIRE) -- Theratechnologies Inc. (“Theratechnologies” or the “Company”) (TSX: TH) (NASDAQ: THTX), a biopharmaceutical company focused on. Stockhouse. Contact Email communications@theratech. Theratechnologies reduces R&D head count to compensate for sales setback. 89 $2. This peptide-drug conjugate (PDC) is the lead candidate stemming from Theratechnologies’ SORT1+ Technology™ in oncology. $103. The firm offers its product under the brand name of. com. (“Theratechnologies” or “the Company”) (TSX: TH) (NASDAQ: THTX), a. Theratechnologies (TSX: TH) (NASDAQ: THTX) is a biopharmaceutical company focused on the development and commercialization of innovative therapies addressing unmet medical needs. (Theratechnologies, or Company) (TSX: TH) (NASDAQ: THTX), a biopharmaceutical company focused on the development and. This news release constitutes a “designated news release” for the purposes of the Company’s prospectus supplement dated December 16, 2021 to its. By continuing to use our service, you agree to our use of cookies. By continuing to use our service, you agree to our use of cookies. Theratechnologies Inc. We currently market prescription products for people with HIV in the United States. com uses cookies on this site. 25 to $1. Image source: The Motley Fool. 124. The company develops treatments for lipodystrophy . MONTREAL, March 31, 2022 (GLOBE NEWSWIRE) -- Theratechnologies Inc. Montréal, Québec, Canada . Theratechnologies (TSX: TH) (NASDAQ: THTX) is a biopharmaceutical company focused on the development and commercialization of innovative therapies addressing unmet medical needs. Stay up to date on the latest stock price, chart, news, analysis, fundamentals, trading and investment tools. (“Theratechnologies” or the “Company”) (TSX: TH) (NASDAQ: THTX), a biopharmaceutical company focused on the development and commercialization of innovative therapies, today presented data suggesting that tesamorelin may improve metabolic profiles in people with HIV. Amount of cash a business has after it has met its financial obligations such as debt and outstanding payments. Theratechnologies Reports Financial Results for the Third Quarter and Nine Months of Fiscal 2023 and Provides Business Updates. By continuing to use our service, you agree to our use of cookies. (THTX) stock. Vice President, Communications and Corporate Affairs. , a biopharmaceutical company focused on the development and commercialization of innovative therapies, announced further changes to its operations that will see a tapering. com uses cookies on this site. Stockhouse. MONTREAL, Sept. Theratechnologies Announces Fiscal Year 2023 Guidance and Operating Plan’s Key Objectives. It is the Company’s proprietary peptide linked to docetaxel – a commonly used cytotoxic agent used to treat many cancers. com uses cookies on this site. Consensus forecasts updated Jul 21. 72%. Theratechnologies (TSX: TH) (NASDAQ: THTX) is a biopharmaceutical company focused on the development and commercialization of innovative therapies addressing unmet medical needs. Data presented at AMCP Nexus 2023. Theratechnologies Announces Certain Preliminary Q3 2023 Financial Highlights. Stockhouse. This news release constitutes a “designated news release” for the purposes. 23 to a day high of $1. FAQ – Utilisateurs de TMX Argent NOUVEAU. MONTREAL, Sept. 2015 Peel Street, 11th Floor Montréal, Québec Canada H3A 1T8 Phone: 514 336-7800 Fax: 514 331-9691. . 4%. com uses cookies on this site. 08 (+6. was a. 63. (“Theratechnologies” or the “Company”) (TSX: TH) (NASDAQ: THTX) today announced the publication of a preclinical study demonstrating the in vitro and in vivo efficacy of TH1902, an investigational sortilin (SORT1)-targeted peptide-drug conjugate, in inhibiting ovarian cancer and triple-negative breast cancer (TNBC. View real-time stock prices and stock quotes for a full financial overview. Canadian Commercial-Stage Biopharmaceutical Company Theratechnologies Announces NASDAQ Listing. . Stockhouse. The company was. Phone Number 15143319691. , a biopharmaceutical company, focuses on the development and commercialization of various therapies to address the unmet medical needs in the United States, Canada, and Europe. The Canadian company develops peptide sequences to treat endocrine and metabolic conditions such as growth hormone deficiencies. If you change your Facebook permissions to restrict Stockhouse from receiving your email while joining or. 12, 2019 (GLOBE NEWSWIRE) -- Theratechnologies Inc. Theratechnologies (TSX: TH) (NASDAQ: THTX) is a commercial-stage biopharmaceutical company addressing unmet medical needs by bringing to market specialized therapies for people with orphan medical. We also use them to share usage. 18, 2023 (GLOBE NEWSWIRE) -- Theratechnologies Inc. 617-356-1009. 10% least volatile stocks in CA Market. Find the latest Theratechnologies Inc. . By continuing to use our service, you agree to our use of cookies. 2015 Peel Street, 11th Floor Montréal, Québec Canada H3A 1T8 Phone: 514 336-7800 Fax: 514 331-9691 Theratechnologies Announces Amendment to its Term Loan Facility With Affiliates of Marathon Asset Management. Theratechnologies Inc. THERATECHNOLOGIES INC. 's motion for leave to commence. Stockhouse. Theratechnologies, Inc. Theratechnologies (TSX: TH) (NASDAQ: THTX) is a biopharmaceutical company focused on the development and commercialization of innovative therapies addressing unmet medical needs. MONTREAL, Nov. (CSE: KOG) (" KO Gold " or the " Company ") is pleased to announce that the common shares of the Company will commence trading on the Canadian Securities Exchange (CSE) effective at the open of business on Wednesday, October 11, 2023, under the symbol " KOG ". (“Theratechnologies” or the “Company”) (TSX: TH) (NASDAQ: THTX), a biopharmaceutical company focused on the development and commercialization of innovative therapies, today announced receipt of a notification letter (the “Notification Letter. com. Stockhouse. 30, 2023 (GLOBE NEWSWIRE) -- Theratechnologies Inc. Theratechnologies (TSX: TH) (NASDAQ: THTX) is a biopharmaceutical company focused on the development and commercialization of innovative therapies addressing unmet medical needs. MONTREAL, Jan. 54% and a negative trailing twelve-month return on equity of 1,116. Cookies are used to offer you a better browsing experience and to analyze our traffic. Fri, 17 Apr 2015 15:08:33 GMT ~ Supreme Court of Canada rules in favour of Theratechnologies. NCU. Small cap stock market news and analysis, portfolio tracking, investor message boards and forums (bullboards), newsletter aggregation and detailed snapshots of stock quotes for. 1-438. In 2022, THTX's revenue was 80. Pour les émetteurs. European Headquarters. Approximately US$2,000,000, or CA$2,600,000, was paid in cash at closing. “This is yet another major achievement for our oncology program. Real-time Price Updates for Theratechnologies (TH-T), along with buy or sell indicators, analysis, charts, historical performance, news and more(2018-03-06 | TSX:TH) Theratechnologies Announces FDA Approval of Breakthrough Therapy, Trogarzo™ (ibalizumab-uiyk) Injection, the First HIV-1 Inhibitor and Long-Acting Monoclonal Antibody for Multidrug Resistant HIV-1. Theratechnologies’ Ibalizumab Demonstrates Cost-Effectiveness as an Addition to Routine Clinical Care in Heavily Treatment-Experienced People with HIV. MONTREAL, Oct. com uses cookies on this site. 18, 2023 (GLOBE NEWSWIRE) -- Theratechnologies Inc. Further information about Theratechnologies is available on the Company's website at , on SEDAR at and on EDGAR at . Stockhouse. stock price gained 1. By continuing to use our service, you agree to our use of cookies. View analysts price targets for THTX. 2015 Peel, 11th Floor Montreal, Quebec H3A 1T8 THERA technologies MANAGEMENT’S DISCUSSION AND ANALYSIS FOR THE YEAR ENDED NOVEMBER 30, 2021 The following Management’s Discussion and Analysis, or MD&A, provides Management’s point of view on the financial position and results of operations. 26, 2022 (GLOBE NEWSWIRE) -- Theratechnologies Inc. (2022-10-26 | TSX:TH) Theratechnologies Reports Data Showing High Expression of Sortilin (SORT1) in Multiple Solid Tumors from Tissue Microarrays Stockhouse. : Renegotiated Lease to Generate Substantial Annual Savings Stockhouse. This suggests a possible upside of 2,471. Stockhouse. MONTREAL, April 08, 2022 (GLOBE NEWSWIRE) -- Theratechnologies Inc. (“Theratechnologies” or the “Company”) (TSX: TH) (NASDAQ: THTX), a biopharmaceutical company focused on the development. (TSX: TH, Forum) noted that its Q1 2022 consolidated sales grew 20%, supported by 35% growth in sales of EGRIFTA SV formulation. 00. Montréal, Québec, Canada . 86 million for the quarter. $44. Senior Director, Investor Relations. com uses cookies on this site. Theratechnologies is a clinical-stage biopharmaceutical company focused on the development and commercialization of innovative therapies. However, only about 4% of the stocks on the OTC market fall into this category. By exploiting the SORT1 function in ligand internalization, a new anticancer treatment strategy was designed to target SORT1‐positive TNBC‐derived cells both in vitro and in two in vivo tumor xenografts. 617-356-1009. Theratechnologies (TSX:TH)has indicated that Trogarzo did not meet its primary endpoints in its IM method study. is a pharmaceutical company, which engages in addressing medical needs of patients with Human Immunodeficiency Virus (HIV). 31K. “Theratechnologies’ commitment to investors at the beginning of 2023 has been to remain steadfast in delivering on key financial objectives, particularly to achieve positive adjusted EBITDA by the end of the current fiscal year,” said Philippe Dubuc, Senior Vice President and Chief Financial Officer at Theratechnologies. stockhouse. Heures de négociation. By continuing to use our service, you agree to our use of cookies. Learn why it. MONTREAL, Aug. 89 52. - Q3 2022 Consolidated Revenue Growth of 17% to $20. THTX earnings call for the period ending February 29, 2020. Theratechnologies Inc. 6. Story. Apr 14, 2020, 8:30 a. Cookies are used to offer you a better browsing experience and to analyze our traffic. 01, 2022 (GLOBE NEWSWIRE) -- Theratechnologies Inc. About Theratechnologies Theratechnologies (TSX: TH) (NASDAQ: THTX) is a biopharmaceutical company focused on the development and commercialization of innovative therapies addressing unmet medical. (TSX: TH) announced today that the Supreme Court of Canada has granted its appeal and dismissed 121851 Canada Inc. com uses cookies on this site. UN) today announces steps to strengthen its financial position, including financing and disposition initiatives, and a reduction to its monthly distribution. By continuing to use our service, you agree to our use of cookies. By continuing to use our service, you agree to our use of cookies. We also use them to share usage information with our partners. Saint-Laurent, Canada. About SORT1+ Technology™ and TH1902. By continuing to use our service, you agree to our use of cookies. Theratechnologies Inc. Theratechnologies had a negative net margin of 36. com uses cookies on this site.